Total Payments
$555.08
2024 Payments
$199.98
Companies
5
Transactions
15
Medicare Patients
3,877
Medicare Billing
$1.2M
Payment Breakdown by Category
Education$289.98 (52.2%)
Food & Beverage$265.10 (47.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $289.98 | 3 | 52.2% |
| Food and Beverage | $265.10 | 12 | 47.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $289.98 | 3 | $0 (2024) |
| Lilly USA, LLC | $99.00 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $84.43 | 5 | $0 (2023) |
| PFIZER INC. | $69.67 | 5 | $0 (2018) |
| Amgen Inc. | $12.00 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $199.98 | 2 | Janssen Biotech, Inc. ($199.98) |
| 2023 | $111.89 | 2 | Janssen Biotech, Inc. ($90.00) |
| 2021 | $33.89 | 2 | Novartis Pharmaceuticals Corporation ($33.89) |
| 2020 | $12.00 | 1 | Amgen Inc. ($12.00) |
| 2019 | $28.65 | 2 | Novartis Pharmaceuticals Corporation ($28.65) |
| 2018 | $13.69 | 1 | PFIZER INC. ($13.69) |
| 2017 | $154.98 | 5 | Lilly USA, LLC ($99.00) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Immunology | ||||||
| 04/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Immunology | ||||||
| 11/22/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Dermatology | ||||||
| 11/08/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $90.00 | General |
| Category: Immunology | ||||||
| 09/22/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: IMMUNOLOGY | ||||||
| 03/30/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: IMMUNOLOGY | ||||||
| 02/26/2020 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: Inflammation | ||||||
| 10/23/2019 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: IMMUNOLOGY | ||||||
| 07/12/2019 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $12.37 | General |
| Category: IMMUNOLOGY | ||||||
| 06/14/2018 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/14/2017 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/25/2017 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/02/2017 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/08/2017 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $10.33 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/21/2017 | Lilly USA, LLC | FORTEO (Drug) | Food and Beverage | In-kind items and services | $99.00 | General |
| Category: Bone Muscle Joint | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 754 | 7,664 | $352,600 | $189,963 |
| 2022 | 20 | 903 | 9,255 | $403,727 | $222,197 |
| 2021 | 21 | 1,066 | 16,935 | $1.0M | $564,582 |
| 2020 | 22 | 1,154 | 11,203 | $511,585 | $261,058 |
Total Patients
3,877
Total Services
45,057
Medicare Billing
$1.2M
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 68 | 6,300 | $155,700 | $114,512 | 73.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 202 | 409 | $50,165 | $26,080 | 52.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 100 | 128 | $20,260 | $13,559 | 66.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 81 | 205 | $31,395 | $11,736 | 37.4% |
| J7324 | Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | Office | 2023 | 21 | 113 | $58,630 | $10,761 | 18.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $6,750 | $3,962 | 58.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 69 | $13,800 | $3,648 | 26.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 67 | 113 | $3,390 | $1,359 | 40.1% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 27 | 27 | $6,300 | $1,132 | 18.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 24 | $1,540 | $1,006 | 65.3% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 72 | 159 | $1,280 | $862.24 | 67.4% |
| 72110 | X-ray of lower and sacral spine, minimum of 4 views | Office | 2023 | 14 | 14 | $1,890 | $589.29 | 31.2% |
| 73560 | X-ray of knee, 1-2 views | Office | 2023 | 11 | 18 | $1,170 | $546.12 | 46.7% |
| J1020 | Injection, methylprednisolone acetate, 20 mg | Office | 2023 | 30 | 55 | $330.00 | $211.29 | 64.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 77 | 7,560 | $189,000 | $129,195 | 68.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 236 | 571 | $71,375 | $39,525 | 55.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 92 | 217 | $33,465 | $13,649 | 40.8% |
| J7324 | Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | Office | 2022 | 19 | 93 | $51,150 | $10,565 | 20.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 14 | 57 | $11,400 | $6,702 | 58.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 51 | 58 | $9,280 | $5,964 | 64.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $6,525 | $3,899 | 59.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 37 | 53 | $3,445 | $2,274 | 66.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 78 | 131 | $3,930 | $1,648 | 41.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 13 | 27 | $5,400 | $1,596 | 29.6% |
| 73560 | X-ray of knee, 1-2 views | Office | 2022 | 24 | 38 | $2,535 | $1,187 | 46.8% |
About Dr. Raymond Adelizzi, DO
Dr. Raymond Adelizzi, DO is a Rheumatology healthcare provider based in Stratford, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770684169.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raymond Adelizzi, DO has received a total of $555.08 in payments from pharmaceutical and medical device companies, with $199.98 received in 2024. These payments were reported across 15 transactions from 5 companies. The most common payment nature is "Education" ($289.98).
As a Medicare-enrolled provider, Adelizzi has provided services to 3,877 Medicare beneficiaries, totaling 45,057 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Stratford, NJ
- Active Since 09/26/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1770684169
Products in Payments
- TREMFYA (Drug) $289.98
- FORTEO (Drug) $99.00
- XELJANZ (Drug) $69.67
- COSENTYX (Biological) $62.54
- COSENTYX (Drug) $21.89
- Enbrel (Biological) $12.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.